**TERT-CLPTM1L Polymorphism rs401681 Contributes to Cancers Risk: Evidence from a Meta-Analysis Based on 29 Publications**

Jieyun Yin¹, Yangkai Li²*, Ming Yin³, Jingwen Sun¹, Li Liu¹, Qin Qin¹, Xiaorong Li¹, Lu Long¹, Shaofa Nie¹*, Sheng Wei¹*

1 Department of Epidemiology and Biostatistics and MOE Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 2 Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 3 Department of Internal Medicine, Geisinger Medical Center, Danville, Pennsylvania, United States of America

**Abstract**

**Background:** Some common genetic variants of TERT-CLPTM1L gene, which encode key protein subunits of telomerase, have been suggested to play a crucial role in tumorigenesis. The TERT-CLPTM1L polymorphism rs401681 was of special interest for cancers risk but with inconclusive results.

**Methodology/Principal Findings:** We performed a comprehensive meta-analysis of 29 publications with a total of 91263 cases and 735952 controls. We assessed the strength of the association between rs401681 and overall cancers risk and performed subgroup analyses by cancer type, ethnicity, source of control, sample size and expected power. Rs401681 C allele was found to be associated with marginally increased cancers risk, with per allele OR of 1.04 (95%CI = 1.00–1.08, P\textsubscript{heterogeneity}=0.001) and an expected power of 1.000. Following further stratified analyses, the increased cancers risk were discovered in subgroups of lung, bladder, prostate, basal cell carcinomas and Asians, while a declined risk of pancreatic cancer and melanoma were detected.

**Conclusions/Significance:** These findings suggested that rs401681 C allele was a low-penetrance risk allele for the development of cancers of lung, bladder, prostate and basal cell carcinoma, but a potential protective allele for melanoma and pancreatic cancer.

**Introduction**

Telomeres are repetitive (TTAGGG)n sequences into arrays of up to 25 kb and cap the end of linear chromosomes in human cells. They play a key role in counteracting the end-replication losses that occur as a consequence of semiconservative replication of linear DNA molecules [1,2]. They also protect against coding sequence erosion and consequent DNA damage repair, which results in genome instability, chromosomal fusions, and rearrangements [3]. Telomerase and the control of telomere length are intimately linked to the process of tumourigenesis in humans. Telomerase have been showed to play a role in tumor progression and metastasis by activation of the glycolytic pathway and suppression of cancer cell differentiation. Abnormal telomere length has been demonstrated in many cancers [4,5].

5p15.33, which was commonly suggested to mediate the function of telomerase, contains two key genes: Telomerase reverse transcriptase (**TERT**) gene, and cleft lip and palate transmembrane 1 like gene (**CLPTM1L**; alias CRR9; MIM 612505). TERT is one of the main functional subunits of the telomerase enzyme and a key regulator of telomerase. Making use of the telomeric RNA subunit of telomerase as a template for the synthesis of single stranded DNA within the telomere, TERT thereby produce (TTAGGG)n tandem nucleotide repeats [6,7]. TERT is reactivated in cancer cells. Mutations in the coding regions of **TERT** can affect telomerase activity and telomere length, and generate severe clinical phenotypes, including bone marrow failure syndromes and a substantive increase in cancer frequency [8]. Although the function of the **CLPTM1L** is largely unknown, studies have demonstrated that it may be involved in the apoptotic response to genotoxic stress induced by cisplatin, as it encodes a transcript whose over-expression has been shown to induce apoptosis in cisplatin-resistant-sensitive cells [9,10,11,12]. Moreover, the **CLPTM1L** variants are hypothesized to enhance the metabolic activation of the reactive metabolites and/or formation and persistence of DNA adducts [13]. According to
| Author, year of publication | Ethnicity | Genotype method | Source of control | Cancer type | No. of Cases/Controls | MAF | OR (95%CI) | Expected Power |
|-----------------------------|-----------|-----------------|-------------------|-------------|----------------------|-----|-----------|----------------|
| McKay: 2008 [38]            | Caucasian | TaqMan          | Population        | Lung Cancer | 297/13746            | 42.6| 1.19 (1.11–1.28) | 0.589         |
| Wang: 2008 [23]             | Caucasian | Illumina & PCR-based KASP | Mixed          | Lung Cancer | 7491/8721            | 40.7| 1.15 (1.09–1.19) | 0.993         |
| Rafnar: 2009 [13]           | Caucasian | Illumina        | Mixed             | Basal cell carcinoma | 2565/29405  | 44.0| 1.25 (1.18–1.34) | 0.125         |
|                            | Caucasian | Illumina        | Mixed             | Lung cancer  | 4265/34666           | 44.0| 1.15 (1.10–1.22) | 0.921         |
|                            | Caucasian | Illumina        | Mixed             | Bladder cancer | 4147/34988  | 46.5| 1.12 (1.06–1.18) | 0.995         |
|                            | Caucasian | Illumina        | Mixed             | Prostate cancer | 9473/37901 | 44.7| 1.07 (1.03–1.11) | 1.000         |
|                            | Caucasian | Illumina        | Population        | Cervical cancer | 369/28890  | 45.5| 1.31 (1.13–1.51) | 0.113         |
|                            | Caucasian | Illumina        | Mixed             | Breast cancer | 3645/30030 | 44.2| 0.98 (0.94–1.02) | 1.000         |
|                            | Caucasian | Illumina        | Mixed             | Colorectal cancer | 2495/29817 | 44.3| 0.95 (0.92–0.99) | 1.000         |
|                            | Caucasian | Illumina        | Population        | Melanoma     | 2443/30839 | 46.0| 0.88 (0.82–0.95) | 0.933         |
|                            | Caucasian | Illumina        | Population        | Endometrial cancer | 470/28890 | 45.5| 1.21 (1.06–1.38) | 0.451         |
|                            | Caucasian | Illumina        | Population        | Kidney cancer | 987/30722 | 44.2| 1.08 (0.97–1.19) | 0.983         |
|                            | Caucasian | Illumina        | Population        | Lymphoma     | 248/28890 | 45.5| 0.87 (0.72–1.05) | 0.688         |
|                            | Caucasian | Illumina        | Population        | Multiple myeloma | 126/28890 | 45.5| 1.21 (0.93–1.58) | 0.476         |
|                            | Caucasian | Illumina        | Population        | Ovarian cancer | 497/28890 | 45.5| 0.98 (0.84–1.14) | 0.984         |
|                            | Caucasian | Illumina        | Population        | Pancreatic cancer | 301/28890 | 45.5| 0.99 (0.81–1.21) | 0.957         |
|                            | Caucasian | Illumina        | Population        | Squamous cell carcinoma | 547/28890 | 45.5| 1.14 (1.00–1.30) | 0.778         |
|                            | Caucasian | Illumina        | Population        | Stomach cancer | 762/28890 | 45.5| 0.96 (0.86–1.07) | 0.996         |
|                            | Caucasian | Illumina        | Population        | Thyroid cancer | 528/28890 | 45.5| 0.97 (0.85–1.10) | 0.992         |
|                            | Caucasian | Illumina        | Population        | Glioblastoma multiforme | 149/149 | 40.9| 0.90 (0.61–1.34) | 0.655         |
|                            | Stacey: 2009 [24] | Caucasian | Illumina | Mixed | Basal cell carcinoma | 3468/38107 | 45.0| 1.20 (1.13–1.27) | 0.500         |
|                            | Stacey: 2009 [24] | Caucasian | Illumina | Population | Squamous cell carcinoma | 1103/35824 | 45.0| 1.04 (0.94–1.16) | 0.995         |
|                            | Stacey: 2009 [24] | Caucasian | Illumina | Mixed | Melanoma | 3843/41963 | 45.0| 0.86 (0.81–0.91) | 0.891         |
|                            | Zienolddiny: 2009 [10] | Caucasian | TaqMan | Nested in cohort | Lung Cancer | 341/431 | 46.9| 1.20 (0.98–1.47) | 0.500         |
|                            | Gudmundsson: 2010 [40] | Caucasian | Illumina | Mixed | Prostate cancer | 1762/36375 | 42.2| 1.07 (0.86–1.33) | 0.849         |
|                            | Kohno: 2010 [41] | Asian | TaqMan | Mixed | Lung Cancer | 2343/1173 | 33.4| 1.14 (1.01–1.25) | 0.862         |
|                            | Liu: 2010 [42] | Caucasian | TaqMan | Hospital | SCCHN | 1079/1115 | 45.2| 1.05 (0.93–1.18) | 0.988         |
|                            | Miki: 2010 [43] | Asian | Illumina | Population | Lung Cancer | 1004/1900 | 31.9| 1.17 (1.04–1.31) | 0.670         |
|                            | Petersen: 2010 [22] | Mixed | Illumina | Mixed | Pancreatic Cancer | 3532/3642 | 44.7| 0.84 (0.79–0.90) | 0.633         |
|                            | Pooley: 2010 [25] | Caucasian | TaqMan | Mixed | Breast Cancer | 6800/6608 | 44.5| 0.99 (0.94–1.04) | 1.000         |
|                            | Pooley: 2010 [25] | Caucasian | TaqMan | Mixed | Colorectal Cancer | 2259/2181 | 45.0| 0.98 (0.90–1.06) | 1.000         |
|                            | Prescott: 2010 [44] | Caucasian | TaqMan | Mixed | Melanoma | 787/999 | 46.2| 1.01 (0.87–1.19) | 0.980         |
|                            | Prescott: 2010 [44] | Caucasian | TaqMan | Nested in cohort | Endometrial Cancer | 674/1685 | 45.0| 0.97 (0.86–1.32) | 0.981         |
|                            | Rothman: 2010 [45] | Caucasian | Illumina | Mixed | Bladder Cancer | 3526/5117 | 45.2| 1.09 (1.01,1.16) | 0.999         |
|                            | Turnbull: 2010 [46] | Caucasian | Illumina | Mixed | Testicular germ cell tumor | 979/4947 | 44.4| 0.79 (0.71–0.87) | 0.158         |
|                            | Yoon: 2010 [19] | Asian | Affymetrix & TaqMan & Invader assay | Population | Lung Cancer | 1425/3011 | 32.1| 1.26 (1.15–1.40) | 0.182         |
|                            | Beesley: 2011 [47] | Caucasian | IPLEX | Mixed | Serous epithelial ovarian cancer | 801/3247 | 43.0| 0.90 (0.80–1.01) | 0.916         |
|                            | Gago-Dominguez: 2011 [48] | Caucasian | TaqMan | Population | Bladder Cancer | 472/554 | 44.2| 1.18 (0.98–1.41) | 0.573         |
the latest dbSNP database (http://www.ncbi.nlm.nih.gov/SNP),
more than 3001 polymorphisms have been identified in the
TERT-CLPTM1L locus. A series of cancer related single nucleotide
polymorphisms (SNPs) have been reported in this region
[14,15,16,17]. A TERT-CLPTM1L SNP, rs401681 (C>T), located in
the intron 13 of CLPTM1L and 27 kb from the TERT (gene), is
one of the most extensively studied SNPs. It has been reported to
be associated with an increased risk of lung cancer through genome-
wide association studies (GWAS) [18,19,20,21,22]. However, the
reported genetic effects varied across the published studies. For
example, an early study reported that the rs401681 T allele (the
minor allele) was not associated with risk of lung cancer in 341 cases
and 431 controls in Caucasians (P = 0.239) [10], but another
study with 2396 lung cancer cases and 3001 controls showed that
the T allele was associated with a remarkably decreased risk of lung
cancer in the same ethnicity (per allele OR = 0.87; 95% CI = 0.84–
0.92) [23]. Additionally, a recent GWAS composed with 20726
cancer patients and 134650 controls suggested that the rs401681 C
allele was associated with increased risk of lung, bladder, prostate
and basal cell carcinomas [13]. More recently, the rs401681 C allele
was inversely showed protective effect on melanoma risk in a study
of 3943 cutaneous melanoma patients and 41963 controls [24],
while another study did not find any significant association between
rs401681 and risk of melanoma [25].

As above, the results remain controversial and ambiguous.
Meanwhile, a single study might have been underpowered to
detect the overall effects. A quantitative synthesis of the
accumulated data from different studies is important to provide
evidence on the association of rs401681 polymorphism with
cancers risk. Thus, in this study, a comprehensive meta-analysis
including the latest and relevant articles was conducted to explore
whether rs401681 contribute to cancers risk.

### Materials and Methods

We conducted a systematic review and meta-analysis in
accordance with the guidelines provided by the Human Genome
Epidemiology Network [26].

### Search Strategy

A systematic literature searching was performed on PubMed,
HuGE Navigator, Google Scholar and ISI Web of Science up to
the end of July, 2012. The search strategy was based on
combinations of “rs401681”, “TERT”, “telomerase reverse
transcriptase”, “5p15.33,” “CLPTM1L”, or “CLPTM1-like”;
“polymorphism,” “gene,” “variant”, “locus” or “SNP”; “associ-
ation” or “risk”; “tumor”, “cancer”, “malignance”, “neoplasm”
or “carcinoma”. In addition, references of the retrieved articles
were scanned. Reviews, comments, and letters were also checked
for additional studies.

### Inclusion and Exclusion Criteria

Articles which met the following criteria were included: (1)
published in English; (2) the outcome was cancers; (3) tested for
rs401681 polymorphism of TERT-CLPTM1L locus; (4) reported
race and numbers of affected and unaffected subjects; (5) sufficient
data for calculating an odds ratio (OR) with 95 percent confidence
interval (95% CI) in additive model (two studies showed allelic
ORs were also included because of large sample size and powerful
influences [13,24]).

Exclusion criteria were: (1) investigations in subjects with family
cancer risks or cancer-prone disposition; (2) unpublished studies;
(3) abstract, case report, comment, review and editorial; (4)
Whenever reports pertained to overlapping patients, we retained
only the largest study to avoid duplication of information.

### Table 1

| Author, year of publication | Ethnicity | Genotype method | Source of control | Cancer type | No. of Cases/Controls | MAF | OR(95% CI) | Expected Power |
|----------------------------|-----------|----------------|-------------------|-------------|----------------------|-----|------------|---------------|
| Hu2011 [49]                | Asian     | TaqMan         | Population        | Bladder cancer | 500/529               | 33.8 | 1.20(1.00–1.45) | 0.500         |
| Kanetsky2011 [26]          | Caucasian | Affymetrix     | Hospital          | Lung cancer   | 2321/3077             | 32.3 | 1.10(1.01–1.19) | 0.985         |
| Nan:2011 [50]              | Caucasian | TaqMan         | Nested in cohort  | Melanoma     | 208/809               | 43.0 | 0.73(0.59–0.90) | 0.115         |
|                           | Caucasian | TaqMan         | Nested in cohort  | Squamous cell carcinoma | 266/809   | 43.0 | 1.04(0.86–1.28) | 0.912         |
|                           | Caucasian | TaqMan         | Nested in cohort  | Basal cell carcinoma | 283/809   | 43.0 | 1.12(0.92–1.35) | 0.765         |
|                           | Caucasian | Illumina       | Hospital          | Lung Cancer   | 1681/1235             | 45.3 | 1.28(1.15–1.43) | 0.127         |
|                           | Caucasian | PCR-based KASPar | Hospital       | Pancreatic ductal adenocarcinoma | 661/1267 | 42.5 | 0.85(0.74–0.97) | 0.638         |
| Bae:2012 [53]              | Asian     | PCR            | Hospital          | Lung cancer   | 1086/1079             | 31.3 | 1.07(0.94–1.22) | 0.957         |
| Chen:2012 [54]             | Asian     | TaqMan         | Hospital          | Lung cancer   | 195/228               | 27.9 | 0.98(0.73–1.32) | 0.863         |
| Klein:2012 [55]            | Mixed     | MassARRAY      | Nested in cohort  | Prostate cancer | 943/2829  | 45.0 | 0.99(0.89–1.11) | 0.999         |
| Ma:2012 [56]               | Asian     | MassARRAY      | Community         | Bladder cancer | 184/962               | 33.0 | 1.04(0.83–1.32) | 0.880         |
| Willis:2012 [57]           | Caucasian | Illumina       | Community         | Pancreatic cancer | 390/149  | 43.0 | 0.82(0.62–1.10) | 0.468         |
| Zheng:2012 [58]            | African   | Illumina       | Mixed             | Breast cancer  | 1509/1383             | 39.9 | 0.94(0.84,1.05) | 0.986         |

Abbreviations: PCR, polymerase chain reaction; SCCHN,Squamous cell carcinoma of the head and neck. doi:10.1371/journal.pone.0050650.t001
Data Extraction

The following information from each study was extracted by two investigators independently: (1) publication data, first author, year of publication; (2) cancer types; (3) ethnicity, source of control group and genotyping method; (4) minor allele frequency (MAF), genotype information (first priority) and/or additive OR and 95% CI, as additive model could recruit the largest number of subjects compared with any other genetic models in this meta-analysis; (5) for studies including subjects of different cancer types or ethnicities, data were extracted separately; (6) several included articles reported consortium or multistage results with multiple independent populations, if the summary OR did not show, these populations were listed as separated data sets. Discrepancies were resolved through discussion.

Statistical Analysis

Deviation from the Hardy–Weinberg equilibrium (HWE) among controls subjects was tested by a $\chi^2$-test and a $P<0.05$ was considered as significant disequilibrium. The strength of the association between rs401681 polymorphism and overall cancers risk was measured by OR and corresponding 95% CI. Heterogeneity across studies was checked using the Cochran’s $Q$-test and considered significant at $P<0.05$ [27]. When homogeneity existed, the fixed model (Mantel-Haenszel method) was used to calculate the summary ORs and 95% CIs; otherwise, the random-effects model (the DerSimonian and Laird method) was utilized [27]. The quantity $I^2$ that presents the percentage of total variation across studies as a result of heterogeneity was also calculated [28]. The potential source of heterogeneity among studies was explored by stratification and meta-regression analyses. Studies were categorized into different subgroups by type of cancer, ethnicity, source of control, sample size and expected power. If one cancer type contained less than three individual studies, it was combined into the “other cancers” group. When it comes to ethnicity, data sets were categorized as Caucasian, Asian and others. Meta-regression was performed to explore the source of heterogeneity among covariables, such as ethnicities, genotyping methods, source of controls, cancer types, sample size (<1000 and ≥1000 subjects) and expected power (<0.5, 0.5 to 0.8 and >0.8) [29,30]. Inverted funnel plots and the Egger’s test were used to examine publication bias [31]. Additionally, sensitivity analyses were performed by including and excluding studies not in HWE, and by removing sequential of individual studies. What’s more, we estimated the expected power of each individual study and subgroup analyses as determined by the probability of detecting a true association between rs401681 and cancers risk at the 0.05 level of significance, assuming OR of 1.2 (for a risk effect) or 0.83 (for a protective effect), with an alpha level equal to the observed $P$ value [32]. All the $P$ values were two sided, and all analyses were done in STATA statistical software (version 10.0; Stata Corporation, college Station, Texas).

Results

Characteristics of All Included Studies

As shown in Figure 1, 34 eligible original studies which through a comprehensive literature search up to the end of July, 2012, seemed to meet the inclusion criteria. However, after further examination, five studies were excluded because: three studies used subjects with family cancer history or cancer-prone disposition [33,34,35]; one study was overlapped with the study of Rafnar et al and had a smaller sample size [36], one study did not provide sufficient data [37]. Final data pool was consisted of 29 publications with 52 data sets. The research strategy was illustrated in Figure 1 and Table S1.

As shown in Table 1 and Table S2, 91263 cases and 735952 controls were relevant to the association between rs401681 and cancers risk. SNPs in all studies were in agreement with HWE except one study [51]. Of these, there

Figure 1. Literature search and study selection procedures for a meta-analysis of TERT-CLTM1L polymorphism rs401681 and cancers risk.
doi:10.1371/journal.pone.0050650.g001

PLOS ONE | www.plosone.org 4 November 2012 | Volume 7 | Issue 11 | e50650
were 20 population-based or community-based data sets, 20 data sets with mixed controls, six hospital-based data sets, six data sets nested in cohort studies; one data set for cancers of cervical, glioblastoma multiforme, kidney, stomach, thyroid, lymphoma or multiple myeloma, ovarian, colorectal, squamous cell, breast and prostate cancer, eleven data sets of lung cancer. Four data sets were of small sample size (<1000 subjects) and 48 were of large sample size (≥1000 subjects). The number of data sets possessed low (<0.5), moderate (0.5 to 0.8) or high (>0.8) expected power were 9, 12 and 31, respectively. Genotyping methods included Affymetrix, Illumina, MassARRAY, iPLEX and TaqMan and so on.

Among 52 data sets included in this meta-analysis, 41 were conducted in Caucasians, eight in Asians, one was in Africans and

| Study ID | OR (95% CI) | % Weight |
|----------|-------------|----------|
| McKay:2008[38] | 1.19 (1.11, 1.28) | 2.29 |
| Wang:2008[23] | 1.15 (1.09, 1.19) | 2.50 |
| Rafnar:2009[13] | 1.25 (1.18, 1.34) | 2.33 |
| Rafnar:32009[13] | 1.12 (1.06, 1.18) | 2.45 |
| Rafnar:42009[13] | 1.07 (1.03, 1.11) | 2.54 |
| Rafnar:52009[13] | 1.31 (1.15, 1.51) | 1.53 |
| Rafnar:62009[13] | 0.98 (0.94, 1.02) | 2.54 |
| Rafnar:72009[13] | 0.95 (0.92, 0.99) | 2.56 |
| Rafnar:82009[13] | 0.88 (0.82, 0.95) | 2.42 |
| Rafnar:92009[13] | 1.21 (1.06, 1.38) | 1.74 |
| Rafnar:102009[13] | 1.08 (0.97, 1.19) | 2.12 |
| Rafnar:112009[13] | 0.87 (0.72, 1.05) | 1.71 |
| Rafnar:122009[13] | 1.21 (1.03, 1.58) | 0.85 |
| Rafnar:132009[13] | 0.98 (0.84, 1.14) | 1.62 |
| Rafnar:142009[13] | 0.96 (0.81, 1.17) | 1.47 |
| Rafnar:152009[13] | 1.14 (1.00, 1.30) | 1.82 |
| Rafnar:162009[13] | 0.96 (0.86, 1.07) | 2.15 |
| Rafnar:172009[13] | 0.97 (0.85, 1.10) | 2.00 |
| Song:2009[39] | 0.90 (0.61, 1.34) | 0.72 |
| Stacey:12009[24] | 1.20 (1.13, 1.27) | 2.39 |
| Stacey:22009[24] | 0.94 (0.94, 1.16) | 2.12 |
| Stacey:32009[24] | 0.86 (0.81, 0.91) | 2.50 |
| Zienolddiny:2009[10] | 1.20 (0.98, 1.47) | 1.20 |
| Gudmundsson:2010[40] | 1.07 (0.86, 1.33) | 1.25 |
| Kohno:2010[41] | 1.14 (1.01, 1.25) | 2.04 |
| Liu:2010[42] | 1.05 (0.93, 1.18) | 2.00 |
| Miki:2010[43] | 1.17 (1.04, 1.31) | 1.93 |
| Petersen:2010[22] | 0.84 (0.70, 0.99) | 2.47 |
| Pooley:2010[25] | 0.99 (0.94, 1.04) | 2.50 |
| Pooley:2010[25] | 0.98 (0.90, 1.06) | 2.33 |
| Pooley:2010[25] | 1.01 (0.97, 1.05) | 1.74 |
| Prescott:2010[44] | 0.97 (0.85, 1.12) | 1.93 |
| Rothman:2010[45] | 1.06 (1.01, 1.16) | 2.42 |
| Turnbull:2010[46] | 0.79 (0.71, 0.87) | 2.33 |
| Yoon:2010[19] | 1.26 (1.15, 1.40) | 2.00 |
| Beesley:2011[47] | 0.90 (0.80, 1.01) | 2.15 |
| Gago-Dominguez:2011[48] | 1.18 (0.98, 1.41) | 1.37 |
| Gago-Dominguez:2011[48] | 0.92 (0.80, 1.07) | 1.31 |
| Hu:2011[49] | 1.10 (1.01, 1.19) | 2.26 |
| Kanetsky:2011[26] | 0.94 (0.79, 1.12) | 1.71 |
| Nan:2011[50] | 0.73 (0.58, 0.90) | 1.76 |
| Nan:2011[50] | 1.04 (0.86, 1.28) | 1.40 |
| Nan:2011[50] | 1.12 (0.92, 1.35) | 1.37 |
| Pandi:2011[51] | 1.28 (1.15, 1.43) | 1.89 |
| Rizzato:2011[52] | 0.85 (0.74, 0.97) | 2.08 |
| Bae:2012[53] | 1.07 (0.94, 1.22) | 1.89 |
| Chen:2012[54] | 0.98 (0.73, 1.32) | 0.96 |
| Klein:2012[65] | 0.99 (0.89, 1.11) | 2.12 |
| Ma:2012[66] | 1.04 (0.83, 1.32) | 1.20 |
| Willis:2012[57] | 0.92 (0.82, 1.01) | 1.23 |
| Zheng:2012[58] | 0.94 (0.84, 1.05) | 2.15 |
| Overall (I-squared = 87.1%, p = 0.000) | 1.04 (1.00, 1.08) | 100.00 |

Figure 2. ORs of overall cancer risks associated with rs401681 under the additive model by random effects. For each data set, the OR and 95% CI was plotted with a box and a horizontal line. The symbol filled diamond indicates pooled OR and its 95% CI. Stacey1-3 represented studies for cancers of basal cell, squamous cell carcinomas and melanoma, respectively; Rafnar1-17 represented studies for basal cell, lung, bladder, prostate, cervical, breast, colorectal, melanoma, endometrial, kidney, lymphoma, multiple myeloma, ovarian, pancreatic, squamous cell, stomach and thyroid, respectively; Gago-Dominguez1-2 represented studies for bladder cancer in Caucasians and Asians, respectively; Pooley1-3 represented studies for breast, colorectal cancers and melanoma, respectively; Nan1-3 represented studies for melanoma, squamous cell and basal cell carcinomas, respectively.

doi:10.1371/journal.pone.0050650.g002
Table 2. Results from Stratified Analysis of the Rs401681 and Cancer Risk, 2008–2011.

| Category                   | No. of data sets | No. of cases | No. of controls | OR (95% CI) | P     | Q     | P*    | I² (%) | Lb    | Pb    | Expected power |
|---------------------------|------------------|--------------|----------------|-------------|-------|-------|-------|--------|-------|-------|----------------|
| **Overall**               |                  | 52           | 91263          | 73952       |       | 1.04(1.00–1.08) | 0.028 | 395.50 | <0.001 | 87.1 | −0.10 | 0.923 1.000 |
| **Cancer type**           |                  |              |                |             |       |       |       |        |       |       |                  |
| Lung Cancer               | 11               | 25133        | 59267          | 1.16(1.13–1.19) | <0.001 | 10.92 | 0.364 | 8.4    | 0.02  | 0.986 | 1.000 |
| Bladder Cancer            | 5                | 8829         | 42150          | 1.17(1.07–1.15) | <0.001 | 1.79  | 0.774 | 0.62   | 0.578 | 1.000 |
| Melanoma                  | 4                | 7281         | 74610          | 0.87(0.83–0.91) | <0.001 | 6.30  | 0.098 | 52.4   | 0.02  | 0.988 | 0.970 |
| Squamous Cell Carcinoma   | 4                | 2995         | 66638          | 1.06(1.00–1.13) | 0.050  | 1.27  | 0.737 | 0.15   | 0.892 | 1.000 |
| Pancreatic Cancer         | 4                | 4884         | 33948          | 0.85(0.80–0.90) | <0.001 | 2.07  | 0.558 | 0.81   | 0.15  | 0.981 | 1.000 |
| Basal cell carcinoma      | 3                | 6316         | 68321          | 1.22(1.17–1.27) | <0.001 | 1.66  | 0.436 | 0      | −0.79 | 0.576 | 1.000 |
| Breast Cancer             | 3                | 11954        | 38021          | 0.98(0.95–1.01) | 0.189  | 0.71  | 0.701 | 0      | −1.37 | 0.402 | 1.000 |
| Prostate Cancer           | 3                | 12178        | 77105          | 1.06(1.02–1.10) | 0.002  | 1.80  | 0.406 | 0      | −0.71 | 0.605 | 1.000 |
| Other cancers             | 15               | 11693        | 275892         | 0.98(0.93–1.04) | 0.505  |       |       |        |       |       |                  |
| **Ethnicity**             |                  |              |                |             |       |       |       |        |       |       |                  |
| Caucasian                 | 41               | 76211        | 716139         | 1.03(0.99–1.07) | 0.094  | 3.22  | 0.465 | 0      | 0     | 0.666 | 1.000 |
| Lung cancer               | 5                | 16749        | 48799          | 1.17(1.13–1.20) | <0.001 | 3.59  | 0.465 | 0      | 0     | 1.000 |
| Melanoma                  | 4                | 7281         | 74610          | 0.87(0.83–0.91) | <0.001 | 6.30  | 0.098 | 52.4   | 0.02  | 0.988 | 0.970 |
| Squamous Cell Carcinoma   | 4                | 2995         | 66638          | 1.06(1.00–1.13) | 0.074  | 1.27  | 0.737 | 0      | 0     | 1.000 |
| Pancreatic cancer         | 3                | 1352         | 30306          | 0.88(0.78–0.97) | 0.010  | 1.65  | 0.438 | 0      | 0     | 0.880 |
| Bladder cancer            | 3                | 8145         | 40659          | 1.11(1.07–1.15) | <0.001 | 0.88  | 0.645 | 0      | 0     | 1.000 |
| Basal cell carcinoma      | 3                | 6316         | 68321          | 1.22(1.17–1.27) | <0.001 | 1.66  | 0.436 | 0      | 0     | 1.000 |
| Other cancers             | 19               | 33373        | 386806         | 0.99(0.95–1.03) | 0.619  | 73.36 | <0.001 | 75.5   | 0     | 0.428 | 0.990 |
| Asian                     | 8                | 9068         | 11959          | 1.14(1.09–1.19) | <0.001 | 7.47  | 0.382 | 6.3    | −0.85 | 0.428 | 0.990 |
| Others                    | 3                | 5984         | 7854           | 0.91(0.82–1.01) | 0.076  | 7.11  | 0.029 | 71.9   | 0     | 0.958 |
| **Sources of control**    |                  |              |                |             |       |       |       |        |       |       |                  |
| Mixed                     | 20               | 66351        | 352537         | 1.02(0.96–1.07) | 0.417  | 2.74  | 0.313 | 0.72   | 0.482 | 1.000 |
| Population- or Community-based | 20            | 15476        | 368395         | 1.07(1.00–1.14) | 0.030  | 8.16  | <0.001 | 76.7   | −0.12 | 0.906 | 1.000 |
| Hospital-based            | 6                | 6721         | 7648           | 1.08(1.00–1.17) | 0.043  | 11.3  | 0.046 | 55.8   | −1.03 | 0.36  | 0.995 |
| Nested in cohort          | 6                | 2715         | 7372           | 0.99(0.87–1.11) | 0.863  | 15.00 | 0.010 | 66.7   | 0.07  | 0.95  | 0.999 |
| **Sample size**           |                  |              |                |             |       |       |       |        |       |       |                  |
| Small                     | 4                | 1075         | 957            | 0.99(0.85–1.12) | 0.873  | 4.98  | 0.173 | 39.8   | −1.77 | 0.219 | 0.997 |
| Large                     | 48               | 90188        | 734995         | 1.04(1.00–1.08) | 0.042  | 390.27| <0.001 | 88.0   | 0.02  | 0.981 | 1.000 |
| **Expected power**        |                  |              |                |             |       |       |       |        |       |       |                  |
| Low                       | 9                | 8213         | 126226         | 1.10(0.92–1.27) | 0.194  | 116.43| <0.001 | 93.1   | −0.98 | 0.358 | 0.882 |
| Moderate                  | 12               | 14176        | 108914         | 1.07(0.96–1.19) | 0.212  | 108.38| <0.001 | 89.9   | −0.06 | 0.951 | 0.983 |
| High                      | 31               | 68874        | 500812         | 1.02(0.98–1.05) | 0.181  | 163.05| <0.001 | 81.6   | −0.54 | 0.596 | 1.000 |

*P values were calculated from Cochran’s Q test; t and P values were calculated by Egger’s test.
doi:10.1371/journal.pone.0050650.t002
two were of mixed ethnicities. The MAF of control subjects were 44.69% in Caucasians, 32.24% in Asians, 39.90% in Africans, respectively.

Association between the rs401681 and Overall Cancers Risk

Rather than using ORs adjusted by covariables, our estimations were based on the raw data when possible. To assess the effect of adjustment, summary effect of ORs with and without adjustment were compared. Although there were subtle differences between these two sources of ORs in each study, the pooled ORs (95%CI) were nearly identical (Figure S1). These differences were of low impact to the synthesis, which were also suggested by other researchers [59,60,61,62]. Meanwhile, we tried to explore the gap between allelic and additive ORs, and found them were amazing close to each other (Figure S2). As a result, two researches, which only reported allelic ORs for rs401681, were also included to final meta-analysis [13,24].

As shown in Figure 2, the overall meta-analysis showed that rs401681 allele C marginally increased overall cancers risk in additive model (OR = 1.04; 95%CI: 1.00–1.08; PHeterogeneity = 0.001 and I^2 = 87.1%), with an expected power of 1.000.

Stratified Analyses

In the stratified analyses by cancer types, as shown in Table 2, it was found that individuals with the C allele genotypes had higher risk of lung cancer (per allele OR = 1.16, 95%CI = 1.13–1.19; Pheterogeneity = 0.364 and I^2 = 8.40%), bladder cancer (per allele OR = 1.11, 95%CI = 1.07–1.15; P heterogeneity = 0.774 and I^2 = 0), basal cell carcinoma (per allele OR = 1.22, 95%CI = 1.17–1.27; P heterogeneity = 0.436 and I^2 = 0) and prostate cancer (per allele OR = 1.06, 95%CI = 1.02–1.10; P heterogeneity = 0.406 and I^2 = 0), but lower risks of melanoma (per allele OR = 0.87, 95%CI = 0.83–0.91; P heterogeneity = 0.996 and I^2 = 52.4%) and pancreatic cancer (per allele OR = 0.85, 95%CI = 0.80–0.90; P heterogeneity = 0.558 and I^2 = 0). Additionally, C allele also contributed to a marginally higher susceptibility of squamous cell carcinoma (per allele OR = 1.06; 95%CI: 1.00–1.13; P heterogeneity = 0.737 and I^2 = 0). However, no significant association was observed for other cancers.

In terms of subgroup analyses by ethnicity, the associations were significant in Asian populations (per allele OR = 1.14; 95%CI: 1.09–1.19; P heterogeneity = 0.382 and I^2 = 6.30%), while it was borderline significant in Caucasians (per allele OR = 1.03; 95%CI: 0.99–1.07) with high heterogeneity (Q = 322.82, P < 0.001; I^2 = 87.6%). Stratified analysis by cancer types was performed in Caucasians, the results for lung, melanoma, squamous cell, pancreatic; bladder and basal cell carcinomas were the same in Caucasians as that of the overall population because these studies were mostly conducted in Caucasians (Table 2).

Further analyses also showed marginally significant results in hospital-based, population or community-based studies and studies of large sample size or high expected power (Table 2).

Evaluation of Heterogeneity

The source of heterogeneity across studies was explored among covariables, such as ethnicities, genotyping methods, source of controls, cancer types, sample size and expected power. Interesting, cancer types were found to contribute to the heterogeneity across the studies in the overall (Table S3) and subgroups meta-analyses of Caucasians (data not shown).

Sensitivity Analyses

A one-way sensitivity analysis was conducted to assess the influence of each individual study on the combined OR, with each particular data set dropped at a time. A random-effect model was employed when heterogeneity was indicated. Stability of odds ratio estimates was confirmed for association between rs401681 and cancers risk (Figure S3). Meanwhile, after the omission of the study departure from HWE, the results did not alter notably (data not shown).
**Discussion**

In the present meta-analysis, our results suggested that the carriers of rs401681 allele C had increased cancers risk, especially for lung, bladder, prostate and basal cell carcinomas, such effect was still found in subgroup of Asians; whereas decreased risk for melanoma and pancreatic cancer. Further exploration of the functional explanation of this locus is warranted to understand the mechanisms for these associations.

These findings have some degree of biological plausibility. The TERT gene is mapped to chromosome 5p15.33 and consists of 16 mechanisms for these associations. It can encode the catalytic subunit of telomerase, functions as telomere maintenance and may play a role in the determination of cancer risk [63]. TERT protein shows a high-level of expression in many tumors and it possibly contributes to unlimited cell division and carcinogenesis [64,65]. The CLPTM1L gene has been documented to be upregulated in cisplatin-resistant cell lines and linked with cisplatin-induced apoptosis [9], and over-expression of CLPTM1L mRNA have been observed in many cancers [12,13,66]. Variants in this locus are hypothesized to mediate telomere length and be associated with multiple malignancies, including cancers of lung, prostate, urinary bladder, cervix and pancreas [15,20,21,22,67].

The heterogeneity among studies in this meta-analysis was dramatically reduced in stratified analyses by cancer types. It suggested a potential modified effect of TERT-CLPTM1L polymorphisms by tumor origins and the rational of stratified analyses. Therefore, we can infer that rs401681 had cancer-specific contributions and may play different roles in the etiology of different tumor sites [10,19,22,23,25,26,41,42,44,48,50,68]. For example, strikingly increased risk was found in smoking related cancers, such as lung and bladder cancers. It may be explained that CLPTM1L protein may be involved in the apoptosis response of genotoxic stress [9,10,11,12]. Further more, Nan and collaborators observed a suggestive positive relationship between rs401681 C allele and shorter relative telomere length [50]. Rafnar et al. suggested rs401681 C allele might be associated with an acceleration of the gradual shortening of telomeres with age [13]. Rs401681 was also demonstrated to be associated with risk of pancreatic cancer for chromosome ends lacking telomeric repeat sequences was observed in this cancer [69,70]. Possible links between shorter telomeres and decreased risk of melanoma were reported [50,67]. This might be because shorter telomere length conferring a shorter replicative lifespan in melanocytes, thus providing a more stringent barrier to unlimited cell division [67]. Declined melanoma risk might also due to the reduction of nevi size and count in individuals with shorter telomeres [67,71]. Compared to the basal and squamous keratinocytes, melanocytes have a higher tendency to senescence in response to oncogenic stress, rather than undergoing cell apoptosis. In addition, shorter telomere length was reported to be associated with an increased risk of basal cell carcinoma [72]. This is probably suggested the different roles of replicative senescence in basal keratinocytes and melanocytes [72]. However, the exact biological function of rs401681 has not been clarified now. It may be in strong linkage disequilibrium (LD) with other potential functional or causal SNPs. For example, rs402710 located in the intron 15 of CLPTM1L is in strong LD with rs401681 ($r^2 = 0.70$ in CEU, $r^2 = 0.89$ in CHB and $r^2 = 0.759$ in YRI), was predicted to have potential regulate function by SNPInfo and reported to be associated with higher levels of bulky aromatic and hydrophobic DNA adducts [10,73]. Meanwhile, some SNPs in high LD with rs401681 are also predicted to have potential function by SNPInfo, including rs31490 ($r^2 = 0.910$ in CEU), located in the transcription factor binding site of CLPTM1L, and rs414965 with high regulatory potential scores (located in the intron 11 of CLPTM1L, $r^2 = 0.759$ in YRI) [73]. Further investigations were required to explore the role of rs401681 or SNPs in high LD with it in carcinogenesis, especially in various cancer types.

Furthermore, the different LD pattern of these potential functional SNPs with rs401681 in different ethnic populations may explain the different associations between rs401681 and cancer risk. Therefore, genetic backgrounds might explain, to some extent, the somewhat conflicting associations in different populations.

In terms of the control’s sources, the subtotal ORs and 95% CIs for rs401681 varied. The pooled ORs in population or community-based studies were 1.07 (95% CI: 1.00–1.14) in additive model with an expected power of 1.000. Thus, these findings emphasized that the advantages of population based studies, including greater efficiency in sample recruitment, external validity than other study designs [74,75]. There were still some limitations which need to be addressed. First, although no any publication bias was showed in the funnel plot and Egger’s tests, selection bias might still exist as non-English literatures were excluded. Second, the number of published studies was still insufficient for the subgroup analyses of some particular cancer sites, such as endometrial, colorectal and testicular germ cell carcinomas. It might mask or exaggerate possible true associations. Third, due to insufficient genotype frequencies, we were unable to calculate the pooled ORs in other genetic models except additive model. Four, ORs with and without adjustment were pooled together, although there was no substantial changes between these two kinds of ORs in this synthesis, it might be a consideration source of heterogeneity. However, after restricting to crude estimations, only 24 data sets were available for synthesis. It might be non-representative and bias, which could lead to vastly different conclusions [76]. Additionally, matching was often assumed to account for confounders in case-control studies (the majority of studies were designed as case-control studies and had matched cases and controls in this meta-analysis). Thus, unadjusted findings represent adjustment that was accounted for by study design and not by the statistical methods [61]. However, we placed more emphasis on assessing biases across studies and tried to reduce potential sources of heterogeneity via stratification and sensitivity analyses. High expected powers of significant findings in this meta-analysis revealed great noteworthy and robustness. In view of this, we were confident that the findings in this meta-analysis were reliable and reasonable.

In conclusion, cumulated evidence suggested that rs401681 C allele was a tumor susceptibility allele in the development of lung, bladder, prostate and basal cell carcinomas, but a potential protective allele for pancreatic cancer and melanoma. These results suggested that the TERT-CLPTM1L polymorphism rs401681 may be potential biomarkers of cancer susceptibility. However, the effect on cancers risk may be modified by ethnicity, cancer type, source of controls and sample size. Future studies are required to validate the current findings.
Supporting Information

Figure S1 Additive ORs and corresponding 95% CI with and without adjustment were nearly identical for rs401681. Gago-Dominguez1-2 represented studies for bladder cancer in Caucasians and Asians, respectively; Nan1-3 represented studies for melanoma, squamous cell and basal cell carcinomas, respectively.

(TIF)

Figure S2 Additive ORs (95% CI) and corresponding allelic ORs (95% CI) of each data set for rs401681. Gago-Dominguez1-2 represented studies for bladder cancer in Caucasians and Asians, respectively; Nan1-3 represented studies for melanoma, squamous cell and basal cell carcinomas, respectively.

(TIF)

Figure S3 One-way sensitivity analyses. The pooled odds ratios were calculated by omitting each data set at a time.

(TIF)

References

1. Olsvikov AM (1971) [Principle of marginotomy in template synthesis of polynucleotides]. Dohl Akad Nauk SSSR 201: 1496–1499.
2. Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA (2005) Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet 37: 745–749.
3. Pooley KA, Sandhu MS, Tyrer J, Shah M, Driver KE, et al. (2010) Telomere length in prospective and retrospective cancer case-control studies. Cancer Res 70: 3170–3176.
4. Greider CW, Blackburn EH (1985) Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43: 405–413.
5. Bodnar AG, Ouellette M, Frolick M, Holt SE, Chiu CP, et al. (1998) Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349–352.
6. De Vivo I, Prescott J, Wong JY, Kraft P, Hankinson SE, et al. (2009) A prospective study of relative telomere length and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 18: 1152–1156.
7. Zee RY, Castonguay AJ, Barton NS, Buring JE (2009) Mean telomere length and risk of incident colorectal carcinoma: a prospective, nested case-control approach. Cancer Epidemiol Biomarkers Prev 19: 2280–2282.
8. Baird DM (2010) Variation at the TERT locus and predisposition for cancer. Expert Rev Mol Med 12: e16.
9. Yamasu K, Okamoto A, Isonishi S, Ochiai K, Obata Y (2001) A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis. Biochem Biophys Res Commun 280: 1148–1154.
10. Zienolddiny S, Skaug V, Landvik NE, Ryberg D, Phillips DH, et al. (2009) The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung. Carcinogenesis 30: 1368–1371.
11. Wang R, Hu C, Zhu J (2007) Transcriptional silencing of a novel tERT reporter locus during in vitro differentiation of mouse embryonic stem cells. Mol Biol Cell 18: 669–677.
12. Asakura T, Inoue A, Ohkubo-Uraoka N, Kuroda M, Ishida Y, et al. (2005) Relationship between expression of drug-resistance factors and drug sensitivity in normal human renal proximal tubular epithelial cells in comparison with renal cell carcinoma. Oncol Rep 14: 601–607.
13. Rafan T, Sulem P, Stacey SN, Geller F, Godmundsson J, et al. (2009) Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet 41: 221–227.
14. Hung RJ, McKay JD, Gaboricau V, Boffetta P, Hashibe M, et al. (2008) A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452: 633–637.
15. Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, et al. (2009) A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet 85: 679–691.
16. Shtere S, Hosking FJ, Robertson LB, Dobkins SE, Sanson M, et al. (2009) Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 41: 899–904.
17. Petersen GM, Amundsdottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, et al. (2010) A genome-wide association study identifies pancreatic cancer susceptibility locus on chromosomes 13q22.1, 1q21.2 and 5p15.33. Nat Genet 42: 224–228.
18. Wang Y, Broderick P, Webb E, Wu X, Vijayakrishnan J, et al. (2008) Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 40: 1407–1409.
19. Zee RY, Castonguay AJ, Barton NS, Buring JE (2009) Mean telomere length or cancer risk. Cancer Epidemiol Biomarkers Prev 19: 1862–1865.
20. Kanetsky PA, Mirra N, Vardhanabhuti S, Vaughan DJ, Li M, et al. (2011) A second independent locus within DMR1T1 is associated with testicular germ cell tumor susceptibility. Hum Mol Genet 20: 3109–1117.
21. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
22. Higgins JP, Thomas SG, Freels JS, Altman D (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557–560.
23. Thompson SG, Sharp SJ (1999) Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 18: 2693–2708.
24. Thompson SG, Smith TC, Sharp SJ (1997) Investigating underlying risk as a source of heterogeneity in meta-analysis. Stat Med 16: 2741–2758.
25. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
26. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96: 434–442.
27. Lai P, Vickers HG, Lu Y, Wang Y, Schwartz AG, et al. (2010) Cumulative effect of TERT, TP63, and CYP2A6 polymorphism on individual risk of tobacco-related lung cancer in male Japanese smokers. Journal of Cancer Therapy 2: 690–697.
28. Kilkie AF (2010) Common predisposition alleles for moderately common cancers: bladder cancer. Curr Opin Genet Dev 20: 218–224.
29. Huang BT, Kan D, Modr P, Catalano NJ (2011) Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a “normal” prostate specific antigen and digital rectal examination. Prostate 71: 394–402.

Table S1 Search Strategies (Search on 2012-07-20).

Table S2 Genotype frequencies and Per Allele OR (95%CI) of Each Data Set enrolled.

Table S3 Meta-regression to explore the source of heterogeneity in 52 included data sets.

Author Contributions

Conceived and designed the experiments: SFN SW. Performed the experiments: QQ XRL L. Long. Analyzed the data: JYY YKL L. Liu. Contributed reagents/materials/analysis tools: JYS MY. Wrote the paper: JYY YKL SW.
38. McKay JD, Hung RJ, Gabrieuca V, Boffetta P, Chabrier A, et al. (2008) Lung cancer susceptibility loci at 5p15.33. Nature Genetics 40: 1404–1406.
39. Song W, Ruder AM, Hu L, Li Y, Ni R, et al. (2009) Genetic epidemiology of glioblastoma multiforme: confirmatory and new findings from analyses of human leukocyte antigen alleles and motifs. PLoS One 4: e7157.
40. Gudmundsson J, Beesnacher S, Salem P, Guthjartsson DF, Ofolsson I, et al. (2010) Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels. Science-Translation Medicine 2.
41. Kohno T, Kunimoto H, Shinnuda Y, Shirasuki K, Iishi Y, et al. (2010) Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes. Carcinogenesis 31: 834–841.
42. Liu Z, Li G, Wei S, Niu J, Wang LE, et al. (2010) Genetic variations in TERT-CLPTM1L genes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis 31: 1977–1981.
43. Miki D, Kuhb M, Takashashi A, Yoon KA, Kim J, et al. (2010) Variation in TP53 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. Nat Genet 42: 893–896.
44. Prescott J, McGrath M, Lee IM, Buring JE, De Vivo I (2010) Telomere length and genetic analyses in population-based studies of endometrial cancer risk. Cancer 116: 4275–4282.
45. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, et al. (2010) A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet 42: 978–984.
46. Turnbull C, Rapley EA, Seal S, Perrett D, Renwick A, et al. (2010) Variants near DMR1, TERT and AFTFIP are associated with testicular germ cell cancer. Nat Genet 42: 604–607.
47. Beesley J, Pickett HA, Johnatty SE, Dunning AM, Chen X, et al. (2011) Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers. PLoS One 6: e24987.
48. Gago-Dominguez M, Jiang X, Coms DV, Castelo JE, Stern MJ, et al. (2011) Genetic variations on chromosomes 3p15 and 15q25 and bladder cancer risk: findings from the Los Angeles-Shanghai bladder cancer-case-control study. Carcinogenesis 32: 197–202.
49. Hu Z, Wu C, Shi Y, Guo H, Zhao X, et al. (2011) A genome-wide association study identifies two new lung cancer susceptibility loci at 15q12.12 and 22q12.2 in Han Chinese. Nat Genet 43: 792–796.
50. Nan H, Qureshi AA, Prescott J, De Vivo I, Han J (2011) Genetic variants in telomere-maintaining genes and skin cancer risk. Hum Genet 129: 247–253.
51. Pande M, Spitz MR, Wu X, Geelov IP, Chen WV, et al. (2011) Novel genetic variants in the chromosome 3p15.33 region associate with lung cancer risk. Carcinogenesis 32: 1493–1499.
52. Rizzato C, Campa D, Giese N, Werner J, Rachakonda PS, et al. (2011) Pancreatic cancer susceptibility Loci and their role in survival. PLoS One 6: e27921.
53. Rae EY, Lee SY, Kang BK, Lee EJ, Choi YY, et al. (2012) Replication of results of genome-wide association studies on lung cancer susceptibility loci in a Korean population. Respiriology.
54. Chen XF, Cai S, Chen QG, Ni ZH, Tang HJ, et al. (2012) Multiple variants of TERT and CLPTM1L constitute risk factors for lung adenocarcinoma. Genet Mol Res 11: 370–378.
55. Klein RJ, Hallden C, Gupta A, Savage CJ, Dahlin A, et al. (2012) Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. Eur Urol 61: 471–477.
56. Ma Z, Hu Q, Chen Z, Tao S, Macnamara L, et al. (2012) Systematic evaluation of bladder cancer risk-associated single-nucleotide polymorphisms in a Chinese population. Mol Carcinog.